Klotho Neurosciences Stock Performance
| KLTO Stock | 0.34 0.01 3.03% |
The company secures a Beta (Market Risk) of 2.87, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Klotho Neurosciences will likely underperform. At this point, Klotho Neurosciences has a negative expected return of -0.8%. Please make sure to verify Klotho Neurosciences' jensen alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Klotho Neurosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Klotho Neurosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Is Klotho Neurosciences Inc. stock in correction or buying zone - July 2025 Setups Expert Verified Stock Movement Alerts - newser.com | 10/28/2025 |
2 | Klotho Neurosciences, Inc. Sees Significant Drop in Short Interest | 11/05/2025 |
3 | How institutional buying supports Klotho Neurosciences Inc. Equity Warrant stock - Market Risk Analysis Risk Controlled Swing Alerts - newser.com | 11/13/2025 |
4 | Klotho Neurosciences enters securities purchase agreement - MSN | 12/09/2025 |
5 | Acquisition by El-dada Riad Hussein of 20000 shares of Klotho Neurosciences, at 0.41 subject to Rule 16b-3 | 12/10/2025 |
6 | Klotho Neurosciences to Present at the Biotech Showcase 2026 - Yahoo Finance | 01/08/2026 |
| Begin Period Cash Flow | 2808.00 | |
| Total Cashflows From Investing Activities | -123.5 K | |
| Free Cash Flow | -3.1 M |
Klotho Neurosciences Relative Risk vs. Return Landscape
If you would invest 62.00 in Klotho Neurosciences on October 12, 2025 and sell it today you would lose (28.00) from holding Klotho Neurosciences or give up 45.16% of portfolio value over 90 days. Klotho Neurosciences is currently does not generate positive expected returns and assumes 5.8987% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Klotho, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Klotho Neurosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Klotho Neurosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Klotho Neurosciences, and traders can use it to determine the average amount a Klotho Neurosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.135
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KLTO |
Based on monthly moving average Klotho Neurosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Klotho Neurosciences by adding Klotho Neurosciences to a well-diversified portfolio.
Klotho Neurosciences Fundamentals Growth
Klotho Stock prices reflect investors' perceptions of the future prospects and financial health of Klotho Neurosciences, and Klotho Neurosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Klotho Stock performance.
| Return On Equity | -1.98 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 26.04 M | ||||
| Shares Outstanding | 72.54 M | ||||
| Price To Book | 2.50 X | ||||
| EBITDA | (5.79 M) | ||||
| Net Income | (6.15 M) | ||||
| Total Debt | 271.75 K | ||||
| Book Value Per Share | 0.14 X | ||||
| Cash Flow From Operations | (2.95 M) | ||||
| Earnings Per Share | (0.30) X | ||||
| Market Capitalization | 24.84 M | ||||
| Total Asset | 2.46 M | ||||
| Retained Earnings | (10.56 M) | ||||
| Working Capital | (1.09 M) | ||||
About Klotho Neurosciences Performance
By examining Klotho Neurosciences' fundamental ratios, stakeholders can obtain critical insights into Klotho Neurosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Klotho Neurosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (44.82) | (47.06) | |
| Return On Capital Employed | (5.27) | (5.00) | |
| Return On Assets | (2.88) | (2.73) | |
| Return On Equity | (5.97) | (5.67) |
Things to note about Klotho Neurosciences performance evaluation
Checking the ongoing alerts about Klotho Neurosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Klotho Neurosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Klotho Neurosciences generated a negative expected return over the last 90 days | |
| Klotho Neurosciences has high historical volatility and very poor performance | |
| Klotho Neurosciences has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (6.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Klotho Neurosciences generates negative cash flow from operations | |
| Klotho Neurosciences has a poor financial position based on the latest SEC disclosures | |
| About 21.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Klotho Neurosciences to Present at the Biotech Showcase 2026 - Yahoo Finance |
- Analyzing Klotho Neurosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Klotho Neurosciences' stock is overvalued or undervalued compared to its peers.
- Examining Klotho Neurosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Klotho Neurosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Klotho Neurosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Klotho Neurosciences' stock. These opinions can provide insight into Klotho Neurosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Klotho Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Klotho Stock, please use our How to Invest in Klotho Neurosciences guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Klotho Neurosciences. If investors know Klotho will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Klotho Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Klotho Neurosciences is measured differently than its book value, which is the value of Klotho that is recorded on the company's balance sheet. Investors also form their own opinion of Klotho Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is Klotho Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Klotho Neurosciences' market value can be influenced by many factors that don't directly affect Klotho Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Klotho Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Klotho Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Klotho Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.